Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a placebo-controlled study of MBS2320 in active rheumatoid arthritis on methotrexate
2016-004038-24Phase 2Completed
- Sponsor
- Modern Biosciences
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing MBS2320 plus methotrexate with Placebo plus methotrexate (2 arms). Primary endpoint: Safety and tolerability. Started May 2022; status: completed.
02
Drugs
Leramistat
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-004038-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004038-24.